【复旦张江：盐酸多柔比星脂质体注射液降价幅度不低于35%】金十数据4月30日讯，复旦张江公告，公司决定自2025年5月1日起调整盐酸多柔比星脂质体注射液市场零售价格，相比此前中标价格降价幅度不低于35%。该药物2024年度销售收入约为人民币2.1亿元，占公司全年销售收入的29%。预计价格调整将对公司2025年度及后续执行期间的销售收入产生不利影响，可能导致该药物2025年度出现单产品亏损的风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.